AMRI names quality control director for troubled plant, following lead of J&J, Novartis, others

Another pharmaceutical manufacturer has announced that it is beefing up quality control management after running afoul of FDA inspectors. AMRI ($AMRI) has named Tom McGrath as director of quality for aseptic services at its Burlington, MA, facility, which last year was cited in an FDA warning letter. A string of companies including Johnson & Johnson ($JNJ), Novartis ($NVS) and Hospira ($HSP) have recently named new leaders ranging from the plant level to the executive suite, whose focus, at least in part, will be on improving GMP in plants. Release | Story

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.